Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 131

1.

High viral load and elevated angiogenic markers associated with increased risk of preeclampsia among women initiating highly active antiretroviral therapy in pregnancy in the Mma Bana study, Botswana.

Powis KM, McElrath TF, Hughes MD, Ogwu A, Souda S, Datwyler SA, von Widenfelt E, Moyo S, Nádas M, Makhema J, Machakaire E, Lockman S, Essex M, Shapiro RL.

J Acquir Immune Defic Syndr. 2013 Apr 15;62(5):517-24. doi: 10.1097/QAI.0b013e318286d77e.

2.

Circulating angiogenic factors and the risk of preeclampsia.

Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, Schisterman EF, Thadhani R, Sachs BP, Epstein FH, Sibai BM, Sukhatme VP, Karumanchi SA.

N Engl J Med. 2004 Feb 12;350(7):672-83. Epub 2004 Feb 5.

3.

Therapeutic levels of lopinavir in late pregnancy and abacavir passage into breast milk in the Mma Bana Study, Botswana.

Shapiro RL, Rossi S, Ogwu A, Moss M, Leidner J, Moffat C, Lockman S, Moyo S, Makhema J, Essex M, Capparelli E.

Antivir Ther. 2013;18(4):585-90. doi: 10.3851/IMP2474. Epub 2012 Nov 26.

PMID:
23183881
4.

Soluble fms-like tyrosine kinase-1 and soluble endoglin in HIV-associated preeclampsia.

Govender N, Naicker T, Rajakumar A, Moodley J.

Eur J Obstet Gynecol Reprod Biol. 2013 Sep;170(1):100-5. doi: 10.1016/j.ejogrb.2013.05.021. Epub 2013 Jun 24.

PMID:
23806447
5.

Changes in circulating concentrations of soluble fms-like tyrosine kinase-1 and placental growth factor measured by automated electrochemiluminescence immunoassays methods are predictors of preeclampsia.

Leaños-Miranda A, Campos-Galicia I, Isordia-Salas I, Rivera-Leaños R, Romero-Arauz JF, Ayala-Méndez JA, Ulloa-Aguirre A.

J Hypertens. 2012 Nov;30(11):2173-81. doi: 10.1097/HJH.0b013e328357c0c9.

PMID:
22902831
6.

The role of angiogenic and antiangiogenic factors in the second trimester in the prediction of preeclampsia in pregnant women with type 1 diabetes.

Holmes VA, Young IS, Patterson CC, Maresh MJ, Pearson DW, Walker JD, McCance DR; Diabetes and Preeclampsia Intervention Trial (DAPIT) Study Group..

Diabetes Care. 2013 Nov;36(11):3671-7. doi: 10.2337/dc13-0944. Epub 2013 Aug 6.

7.

Time to viral load suppression in antiretroviral-naive and -experienced HIV-infected pregnant women on highly active antiretroviral therapy: implications for pregnant women presenting late in gestation.

Aziz N, Sokoloff A, Kornak J, Leva NV, Mendiola ML, Levison J, Feakins C, Shannon M, Cohan D.

BJOG. 2013 Nov;120(12):1534-47. doi: 10.1111/1471-0528.12226. Epub 2013 Aug 7.

8.

Antiretroviral regimens in pregnancy and breast-feeding in Botswana.

Shapiro RL, Hughes MD, Ogwu A, Kitch D, Lockman S, Moffat C, Makhema J, Moyo S, Thior I, McIntosh K, van Widenfelt E, Leidner J, Powis K, Asmelash A, Tumbare E, Zwerski S, Sharma U, Handelsman E, Mburu K, Jayeoba O, Moko E, Souda S, Lubega E, Akhtar M, Wester C, Tuomola R, Snowden W, Martinez-Tristani M, Mazhani L, Essex M.

N Engl J Med. 2010 Jun 17;362(24):2282-94. doi: 10.1056/NEJMoa0907736.

9.
10.

Circulating Angiogenic Factors and the Risk of Preeclampsia in Systemic Lupus Erythematosus Pregnancies.

Leaños-Miranda A, Campos-Galicia I, Berumen-Lechuga MG, Molina-Pérez CJ, García-Paleta Y, Isordia-Salas I, Ramírez-Valenzuela KL.

J Rheumatol. 2015 Jul;42(7):1141-9. doi: 10.3899/jrheum.141571. Epub 2015 May 15.

PMID:
25979720
11.

Vasoactive agents for the prediction of early- and late-onset preeclampsia in a high-risk cohort.

Villa PM, Hämäläinen E, Mäki A, Räikkönen K, Pesonen AK, Taipale P, Kajantie E, Laivuori H.

BMC Pregnancy Childbirth. 2013 May 12;13:110. doi: 10.1186/1471-2393-13-110.

12.

Highly active antiretroviral therapy started during pregnancy or postpartum suppresses HIV-1 RNA, but not DNA, in breast milk.

Shapiro RL, Ndung'u T, Lockman S, Smeaton LM, Thior I, Wester C, Stevens L, Sebetso G, Gaseitsiwe S, Peter T, Essex M.

J Infect Dis. 2005 Sep 1;192(5):713-9. Epub 2005 Jul 27.

PMID:
16088820
13.

Placental growth factor and soluble fms-like tyrosine kinase-1 are useful markers for the prediction of preeclampsia but not for small for gestational age neonates: a longitudinal study.

Rizos D, Eleftheriades M, Karampas G, Rizou M, Haliassos A, Hassiakos D, Vitoratos N.

Eur J Obstet Gynecol Reprod Biol. 2013 Dec;171(2):225-30. doi: 10.1016/j.ejogrb.2013.08.040. Epub 2013 Sep 4.

PMID:
24035323
14.

Cigarette smoke exposure and angiogenic factors in pregnancy and preeclampsia.

Jeyabalan A, Powers RW, Durica AR, Harger GF, Roberts JM, Ness RB.

Am J Hypertens. 2008 Aug;21(8):943-7. doi: 10.1038/ajh.2008.219. Epub 2008 Jun 19.

15.

Soluble Fms-like tyrosine kinase-1 to placental growth factor ratio in mid-pregnancy as a predictor of preterm preeclampsia in asymptomatic pregnant women.

Forest JC, Thériault S, Massé J, Bujold E, Giguère Y.

Clin Chem Lab Med. 2014 Aug;52(8):1169-78. doi: 10.1515/cclm-2013-0955.

PMID:
24535301
16.

Soluble endoglin and other circulating antiangiogenic factors in preeclampsia.

Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP, Sibai BM, Epstein FH, Romero R, Thadhani R, Karumanchi SA; CPEP Study Group..

N Engl J Med. 2006 Sep 7;355(10):992-1005. Erratum in: N Engl J Med. 2006 Oct 26;355(17):1840.

17.

Prospective study of placental angiogenic factors and maternal vascular function before and after preeclampsia and gestational hypertension.

Noori M, Donald AE, Angelakopoulou A, Hingorani AD, Williams DJ.

Circulation. 2010 Aug 3;122(5):478-87. doi: 10.1161/CIRCULATIONAHA.109.895458. Epub 2010 Jul 19. Erratum in: Circulation. 2011 Sep 13;124(11):e302.

18.

Highly active antiretroviral therapy versus zidovudine/nevirapine effects on early breast milk HIV type-1 Rna: a phase II randomized clinical trial.

Chung MH, Kiarie JN, Richardson BA, Lehman DA, Overbaugh J, Kinuthia J, Njiri F, John-Stewart GC.

Antivir Ther. 2008;13(6):799-807.

19.

Difference of concentration of placental soluble fms-like tyrosine kinase-1(sFlt-1), placental growth factor (PlGF), and sFlt-1/PlGF ratio in severe preeclampsia and normal pregnancy.

Gurnadi JI, Mose J, Handono B, Satari MH, Anwar AD, Fauziah PN, Yogi Pramatirta A, Rihibiha DD.

BMC Res Notes. 2015 Oct 4;8:534. doi: 10.1186/s13104-015-1506-0.

20.

The relationship between circulating endothelin-1, soluble fms-like tyrosine kinase-1 and soluble endoglin in preeclampsia.

Aggarwal PK, Chandel N, Jain V, Jha V.

J Hum Hypertens. 2012 Apr;26(4):236-41. doi: 10.1038/jhh.2011.29. Epub 2011 Mar 31.

PMID:
21451568

Supplemental Content

Support Center